{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:53Z","timestamp":1758845933357,"version":"3.44.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ucl.2021.12.009","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:53:00Z","timestamp":1649796780000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemodenervation in Urology"],"prefix":"10.1016","volume":"49","author":[{"given":"Meera","family":"Ganesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Kielb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib2","first-page":"24","article-title":"Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study","volume":"71","author":"Dykstra","year":"1990","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bju.12028","article-title":"Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox((R)) ) or abobotulinumtoxinA (Dysport((R)) ) make a difference?","volume":"112","author":"Ravindra","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/nau.23009","article-title":"Intradetrusor injections of onabotulinum toxin A (Botox(R)) 300 U or 200 U versus abobotulinum toxin A (Dysport(R)) 750 U in the management of neurogenic detrusor overactivity: A case control study","volume":"36","author":"Peyronnet","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ucl.2021.12.009_bib6","series-title":"Biology and mechanism of action. Botulinum toxin in Urology","first-page":"13","author":"Chancellor","year":"2011"},{"year":"2006","series-title":"Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions","author":"Aronson","key":"10.1016\/j.ucl.2021.12.009_bib7"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0003-9861(54)90013-2","article-title":"Isolation and sedimentation study of low molecular weight forms of type A botulinus toxin","volume":"50","author":"Wagman","year":"1954","journal-title":"Arch Biochem Biophys"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.009_bib10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1021\/bi992321x","article-title":"Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain","volume":"39","author":"Li","year":"2000","journal-title":"Biochemistry"},{"issue":"Pt 16","key":"10.1016\/j.ucl.2021.12.009_bib11","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1242\/jcs.112.16.2715","article-title":"Functional characterisation of tetanus and botulinum neurotoxins binding domains","volume":"112","author":"Lalli","year":"1999","journal-title":"J\u00a0Cell Sci"},{"issue":"20","key":"10.1016\/j.ucl.2021.12.009_bib12","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.biochem.6b01246","article-title":"Insights into the mechanisms by which clostridial neurotoxins discriminate between gangliosides","volume":"56","author":"Burns","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.ucl.2021.12.009_bib13","series-title":"Uptake and trafficking of protein toxins","first-page":"1","article-title":"Two feet on the membrane: uptake of clostridial neurotoxins","author":"Rummel","year":"2017"},{"issue":"12","key":"10.1016\/j.ucl.2021.12.009_bib14","doi-asserted-by":"crossref","first-page":"e1000245","DOI":"10.1371\/journal.ppat.1000245","article-title":"Botulinum neurotoxin devoid of receptor binding domain translocates active protease","volume":"4","author":"Fischer","year":"2008","journal-title":"Plos Pathog"},{"issue":"s1","key":"10.1016\/j.ucl.2021.12.009_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","article-title":"Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins","volume":"43","author":"Dolly","year":"2003","journal-title":"Headache"},{"issue":"7019","key":"10.1016\/j.ucl.2021.12.009_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature03123","article-title":"Substrate recognition strategy for botulinum neurotoxin serotype A","volume":"432","author":"Breidenbach","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1464-410X.2007.07137.x","article-title":"Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment","volume":"100","author":"Schulte-Baukloh","year":"2007","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12020098","article-title":"Effect of Botulinum Toxin A on Bladder Pain-Molecular Evidence and Animal Studies","volume":"12","author":"Yeh","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"42","key":"10.1016\/j.ucl.2021.12.009_bib19","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1523\/JNEUROSCI.3023-06.2006","article-title":"Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats","volume":"26","author":"Yoshimura","year":"2006","journal-title":"J\u00a0Neurosci"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.009_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nn902","article-title":"Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1","volume":"5","author":"Birder","year":"2002","journal-title":"Nat Neurosci"},{"issue":"6807","key":"10.1016\/j.ucl.2021.12.009_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/35039519","article-title":"Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice","volume":"407","author":"Cockayne","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib23","first-page":"977","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"24","key":"10.1016\/j.ucl.2021.12.009_bib24","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","article-title":"Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity","volume":"279","author":"Morenilla-Palao","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib25","first-page":"2341","article-title":"Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity","volume":"175","author":"Giannantoni","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1464-410X.2003.04722.x","article-title":"Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment","volume":"93","author":"Brady","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2003.12.017","article-title":"P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin","volume":"46","author":"Brady","year":"2004","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1757-5672.2010.00074.x","article-title":"Sensor mechanism and afferent signal transduction of the urinary bladder: special focus on transient receptor potential ion channels","volume":"2","author":"Takeda","year":"2010","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib29","first-page":"2269","article-title":"Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats","volume":"168","author":"Seki","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2021.12.009_bib30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bju.12266","article-title":"OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium","volume":"112","author":"Collins","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8050126","article-title":"Intraprostatic botulinum neurotoxin type A injection for benign prostatic hyperplasia-A spotlight in reality","volume":"8","author":"Hsu","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8","article-title":"Botox-induced prostatic involution","volume":"37","author":"Doggweiler","year":"1998","journal-title":"The Prostate"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.eururo.2012.03.039","article-title":"Anatomic study of periprostatic nerve distribution: immunohistochemical differentiation of parasympathetic and sympathetic nerve fibres","volume":"62","author":"Ganzer","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2008.07.003","article-title":"Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat","volume":"56","author":"Silva","year":"2009","journal-title":"Eur Urol"},{"year":"2017","series-title":"BOTOX (onabotulinumtoxinA) for injection, for intramuscular, or intradermal use","author":"FDA","key":"10.1016\/j.ucl.2021.12.009_bib35"},{"key":"10.1016\/j.ucl.2021.12.009_bib36","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.ucl.2021.12.009_bib37","article-title":"The prevalence and forecast prevalence of overactive bladder in the medicare population","volume":"12","author":"Puckrein","year":"2019","journal-title":"Clin Med Insights: Urol"},{"key":"10.1016\/j.ucl.2021.12.009_bib38","doi-asserted-by":"crossref","unstructured":"Lightner DJ GA, Souter L et\u00a0al. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA\/SUFU Guideline (2019). Vol. 202. 2019:548. AUA\/SUFU Guideline Ammendment. Accessed 2021.","DOI":"10.1097\/JU.0000000000000309"},{"key":"10.1016\/j.ucl.2021.12.009_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.urology.2016.10.026","article-title":"Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis","volume":"100","author":"Lopez Ramos","year":"2017","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib40","first-page":"7681","article-title":"Botulinum neurotoxin A for overactive bladder treatment: advantages and pitfalls","volume":"22","author":"Chibelean","year":"2015","journal-title":"Can J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ucl.2021.12.009_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2019.02.005","article-title":"The relative efficacy and safety of mirabegron and onabotulinumtoxina in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis","volume":"127","author":"Lozano-Ortega","year":"2019","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib43","first-page":"969","article-title":"Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial","volume":"203","author":"Harvie","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12020128","article-title":"Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis","volume":"12","author":"Lo","year":"2020","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ucl.2021.12.009_bib45","doi-asserted-by":"crossref","unstructured":"Hanno PM ED, Moldwin R et\u00a0al. Diagnosis and Treatment Interstitial Cystitis\/Bladder Pain Syndrome (2014). Vol. 193. 2015:1545. AUA Guideline Ammendment. Accessed 2021.","DOI":"10.1016\/j.juro.2015.01.086"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.009_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11090510","article-title":"Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis\/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis","volume":"11","author":"Giannantoni","year":"2019","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.009_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00192-016-3079-4","article-title":"Intravesical treatment for interstitial cystitis\/painful bladder syndrome: a network meta-analysis","volume":"28","author":"Zhang","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ucl.2021.12.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S0302-2838(21)00694-1","article-title":"The benefits and harms of botulinum toxin-A in the treatment of chronic pelvic pain syndromes: a systematic review by the European Association of Urology Chronic Pelvic Pain Panel","author":"Parsons","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ucl.2021.12.009_bib49","unstructured":"Kevin T. McVary M, Chair; Claus G. Roehrborn, MD, Co-Chair; Andrew L. Avins, MD, MPH; Michael J. Barry, MD; Reginald C. Bruskewitz, MD; Robert F. Donnell, MD; Harris E. Foster, Jr., MD; Chris M. Gonzalez, MD; Steven A. Kaplan, MD; David R. Penson, MD; James C. Ulchaker, MD; John T. Wei, MD. Management of Benign Prostatic Hyperplasia. 2014. Benign Prostatic Hyperplasia (BPH) Guideline. Accessed 2021."},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajur.2017.11.003","article-title":"Botulinum toxin and benign prostatic hyperplasia","volume":"5","author":"Ng","year":"2018","journal-title":"Asian J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib51","doi-asserted-by":"crossref","first-page":"e1079a","DOI":"10.1016\/S1569-9056(16)61080-1","article-title":"1079 A randomized clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox\u00ae) to optimized medical therapy in patients with BPH-related LUTS: End-of-study results of the PROTOX trial","volume":"15","author":"Delongchamps","year":"2016","journal-title":"Eur Urol Supplements"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.009_bib52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11884-018-0482-3","article-title":"Contemporary treatment of detrusor sphincter dyssynergia: a systematic review","volume":"13","author":"Li","year":"2018","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"5","key":"10.1016\/j.ucl.2021.12.009_bib53","first-page":"919","article-title":"Effects of Botulinum a Toxin On Detrusor-Sphincter Dyssynergia In Spinal Cord Injury Patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib54","first-page":"1023","article-title":"Botulinum-A Toxin as a Treatment of Detrusor-Sphincter Dyssynergia: A Prospective Study in 24 Spinal Cord Injury Patients","volume":"155","author":"Schurch","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sc.2015.224","article-title":"Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury","volume":"54","author":"Soler","year":"2016","journal-title":"Spinal Cord"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib56","first-page":"2416","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.ucl.2021.12.009_bib57","first-page":"16","article-title":"Botox may boost QOL in overactive bladder: treatment with 100 U 'may be the best dose in terms of balancing efficacy and safety","volume":"44","author":"Birk","year":"2009","journal-title":"Ob gyn news"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.009_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5213\/inj.1836118.059","article-title":"Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis","volume":"22","author":"Li","year":"2018","journal-title":"Int Neurourol J"},{"issue":"18","key":"10.1016\/j.ucl.2021.12.009_bib59","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1089\/neu.2015.4278","article-title":"Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury","volume":"33","author":"Fougere","year":"2016","journal-title":"J\u00a0Neurotrauma"},{"year":"2016","series-title":"Hinman's Atlas of urologic Surgery","author":"Jr","key":"10.1016\/j.ucl.2021.12.009_bib60"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijcp.12360","article-title":"Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure","volume":"68","author":"Karsenty","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.ucl.2021.12.009_bib62","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/nau.23052","article-title":"Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity","volume":"36","author":"Avallone","year":"2017","journal-title":"Neurourol Urodyn"},{"issue":"13","key":"10.1016\/j.ucl.2021.12.009_bib63","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25582","article-title":"Diffusion, spread, and migration of botulinum toxin","volume":"28","author":"Ramirez-Castaneda","year":"2013","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib64","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11255-015-0976-2","article-title":"Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection","volume":"47","author":"Alsinnawi","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2021.12.009_bib65","first-page":"1359","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/luts.12321","article-title":"Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: A randomized clinical trial","volume":"13","author":"El-Hefnawy","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ucl.2021.12.009_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urology.2019.09.030","article-title":"Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip","volume":"135","author":"Derisavifard","year":"2020","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib68","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00345-016-1847-x","article-title":"Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement","volume":"35","author":"Giannantoni","year":"2017","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2021.12.009_bib69","doi-asserted-by":"crossref","first-page":"33197","DOI":"10.1038\/srep33197","article-title":"Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity","volume":"6","author":"Leitner","year":"2016","journal-title":"Scientific Rep"},{"key":"10.1016\/j.ucl.2021.12.009_bib70","article-title":"Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder","author":"Eckhardt","year":"2021","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ucl.2021.12.009_bib71","article-title":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review","author":"Abrar","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.ucl.2021.12.009_bib72","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00192-017-3440-2","article-title":"What is the true catheterization rate after intravesical onabotulinumtoxinA injection?","volume":"29","author":"Patel","year":"2018","journal-title":"Int Urogynecol J"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00192-014-2499-2","article-title":"Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events","volume":"26","author":"Davis","year":"2015","journal-title":"Int Urogynecol J"},{"issue":"7","key":"10.1016\/j.ucl.2021.12.009_bib74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.009_bib75","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A\u00a0cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int Urogynecol J"},{"issue":"6","key":"10.1016\/j.ucl.2021.12.009_bib76","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.urology.2006.08.1069","article-title":"Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity","volume":"68","author":"Karsenty","year":"2006","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib77","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/nau.23354","article-title":"Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity\u2014A systematic review and meta-analysis","volume":"37","author":"Ni","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ucl.2021.12.009_bib78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2019.12.001","article-title":"Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of a Pilot Study","volume":"137","author":"Mart\u00ednez-Cuenca","year":"2020","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.ucl.2021.12.009_bib79","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1600-0854.2012.01369.x","article-title":"Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport","volume":"13","author":"Restani","year":"2012","journal-title":"Traffic"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cote","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ucl.2021.12.009_bib81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000508854","article-title":"Systemic Botulism Toxicity Caused by Pyloric Botox Injection to Treat Gastroparesis","volume":"14","author":"Bensen","year":"2020","journal-title":"Case Rep Gastroenterol"},{"issue":"3","key":"10.1016\/j.ucl.2021.12.009_bib82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2005.11.009","article-title":"A\u00a0review of WHO International Standards for botulinum antitoxins","volume":"34","author":"Jones","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.ucl.2021.12.009_bib83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2017.11.013","article-title":"Pyridostigmine for the Reversal of Severe Adverse Reactions to Botulinum Toxin in Children","volume":"194","author":"Boerner","year":"2018","journal-title":"J\u00a0Pediatr"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014321019170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:55:19Z","timestamp":1758808519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014321019170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0094014321019170"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemodenervation in Urology","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2021.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}